Editas Medicine Inc (EDIT) — 13F Holders Deep Dive (Q2 2026)

EDIT ranks #2783 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

220 institutions disclose a position in EDIT, but none treat it as a major bet — even GordonMD Global Investments LP, its most concentrated holder, allocates just 4.9% of its own portfolio to it.

GAMMA Investing LLC has added to its EDIT position for two straight quarters, increasing it by $2.4K to reach $5.4K today.

Farther Finance Advisors, LLC has trimmed its EDIT position for two straight quarters, cutting it by $4.1K while still holding $195.0.

EDIT is down 3.7% today, but institutions show net buying of $227.8M this quarter — a divergence between today's price move and the underlying institutional flow.

EDIT reported a net loss of $73.9M over the trailing twelve months.

• Not yet profitable — net loss of $73.9M over the trailing twelve months
• Revenue grew 20.8% year over year
• Net income improved year over year, from -$236.9M to -$73.9M
• Operating cash flow was negative, using $165.2M in cash
• Current ratio of 3.54x — enough short-term assets to cover short-term liabilities
• Liabilities run 5.84x equity — a highly leveraged balance sheet worth noting